As at Jun 3, 2026, the ALKS stock has a PE ratio of 45.98. This is based on the current EPS of $0.93 and the stock price of $42.76 per share. An increase of 117% has been recorded in the P/E ratio compared to the average of 21.2 of the last 4 quarters.
The mean historical PE ratio of Alkermes over the last three years is 19.78. The current 45.98 PE ratio is 132% above the historical average. In the past three years, ALKS's PE ratio was at its highest in the Jun 2023 quarter at 51.31, with a price of $31.3 and an EPS of $0.61. The Mar 2024 quarter recorded the bottom point at 10.33, with a price of $27.07 and an EPS of $2.62.
Maximum annual increase: 46.95% in 2025
Maximum annual decrease: -0.08% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 19.03 | 46.95% | $27.98 | $1.47 |
| 2024 | 12.95 | -0.08% | $28.76 | $2.22 |
| 2023 | 12.96 | N/A | $27.74 | $2.14 |
| 2022 | N/A | N/A | $26.13 | -$0.97 |
| 2021 | N/A | N/A | $23.26 | -$0.3 |
| 2020 | N/A | N/A | $19.95 | -$0.7 |
| 2019 | N/A | N/A | $20.4 | -$1.25 |
| 2018 | N/A | N/A | $29.51 | -$0.9 |
| 2017 | N/A | N/A | $54.73 | -$1.03 |
| 2016 | N/A | N/A | $55.58 | -$1.38 |
| 2015 | N/A | N/A | $79.38 | -$1.52 |
| 2014 | N/A | N/A | $58.56 | -$0.21 |
| 2013 | 124.74 | N/A | $23.7 | $0.19 |
| 2012 | N/A | N/A | $18.55 | -$0.99 |
| 2011 | N/A | N/A | $12.95 | -$0.48 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 38.02 | 99.79% | $35.36 | $0.93 |
| Dec 2025 | 19.03 | 31.33% | $27.98 | $1.47 |
| Sep 2025 | 14.49 | 8.38% | $30 | $2.07 |
| Jun 2025 | 13.37 | -12.96% | $28.61 | $2.14 |
| Mar 2025 | 15.36 | 18.61% | $33.02 | $2.15 |
| Dec 2024 | 12.95 | -7.04% | $28.76 | $2.22 |
| Sep 2024 | 13.93 | 0% | $27.99 | $2.01 |
| Jun 2024 | 13.93 | 34.85% | $24.1 | $1.73 |
| Mar 2024 | 10.33 | -20.29% | $27.07 | $2.62 |
| Dec 2023 | 12.96 | -40.3% | $27.74 | $2.14 |
| Sep 2023 | 21.71 | -57.69% | $28.01 | $1.29 |
| Jun 2023 | 51.31 | N/A | $31.3 | $0.61 |
| Mar 2023 | N/A | N/A | $28.19 | -$1 |
| Dec 2022 | N/A | N/A | $26.13 | -$0.97 |
| Sep 2022 | N/A | N/A | $22.33 | -$0.78 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
ALKS's current P/E ratio is above the 3, 5 and 10-year historical averages.
With a P/E of 45.98, ALKS stands above the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 23.02, Alkermes's P/E is 100% higher.
ALKS's PE ratio is higher than its peer stocks JNJ and NVS. Alkermes is presently trading at a higher PE ratio (45.98) than its peer group average of 21.82.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BMY Bristol Myers Squibb Co | 15.86 | $115.6B |
| PFE Pfizer Inc | 19.61 | $146.42B |
| NVS Novartis AG | 21.14 | $283.17B |
| TEVA Teva Pharmaceutical Industries Ltd | 24.93 | $39.77B |
| JNJ Johnson & Johnson | 26.13 | $549.06B |
| AZN Astrazeneca plc | 27.09 | $281.59B |
| ALKS Alkermes plc | 46.63 | $7.23B |
The price to earnings ratio for ALKS stock as of Jun 3, 2026, stands at 45.98.
As an average over the last 3 years, ALKS stock has a PE ratio of 19.78.
As an average over the last 5 years, ALKS stock has a PE ratio of 19.78.
The highest quarterly PE ratio in the last three years has been 51.31 and it was in the Jun 2023 quarter.
ALKS's current price to earnings ratio is 132% above its 3-year historical average.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Jun 3, 2026), Alkermes's stock price is $42.76. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.93. Therefore, Alkermes's P/E ratio for today is 45.98. PE RATIO(45.98) = STOCK PRICE($42.76) / TTM EPS($0.93)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.